First Trust Advisors LP Macrogenics Inc Transaction History

First Trust Advisors LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$2.25 - $9.99 $56,427 - $250,539	-25,079 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$8.12 - $16.9 $8,834 - $18,387	1,088 Added 4.54%	25,079 $221,000
Q4 2021 Feb 08, 2022	BUY	$15.91 - $21.88 $77,290 - $106,293	4,858 Added 25.39%	23,991 $385,000
Q3 2021 Nov 15, 2021	SELL	$19.74 - $28.7 $2.56 Million - $3.73 Million	-129,925 Reduced 87.16%	19,133 $401,000
Q2 2021 Aug 16, 2021	BUY	$20.49 - $35.63 $2.57 Million - $4.46 Million	125,300 Added 527.4%	149,058 $4 Million
Q1 2021 May 14, 2021	SELL	$18.99 - $33.2 $1.04 Million - $1.82 Million	-54,678 Reduced 69.71%	23,758 $757,000
Q4 2020 Feb 02, 2021	BUY	$19.41 - $26.0 $1.52 Million - $2.04 Million	78,436 New	78,436 $1.79 Million

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

Stay updated on First Trust Advisors LP with notifications on news.